MCL Literature Feed

This SHINE trial analysis shows ibrutinib's PFS benefit with BR is consistent across exposure levels, supporting dose reductions for toxicities like atrial fibrillation without compromising efficacy.

A 2022 real-world Japanese study shows chemotherapy remains dominant frontline while BTKis are common second-line, with physicians prioritizing quality of life for BTKi-treated patients over tumor response.

Adding venetoclax to RBAC chemo-immunotherapy improves 2-year progression-free survival to 60% for older, high-risk MCL patients, validating a new risk-stratified, fixed-duration frontline treatment.

In newly diagnosed MCL, ATM deletion predicts shorter progression-free survival in TP53 wild-type patients, whereas ATM mutation may indicate a better prognosis, highlighting their distinct prognostic roles.

This review summarizes the integration of BTK inhibitors into frontline MCL therapy and the emerging role of MRD, providing a treatment algorithm for managing newly diagnosed patients.

In elderly, frontline MCL, this SHINE secondary analysis shows achieving a complete response is critical for long-term PFS, and adding ibrutinib to BR significantly increases CR rates.

Retrospective data show B symptoms and CBV conditioning negatively impact survival post-ASCT in MCL, supporting BeEAM conditioning and risk-adapted strategies for consolidation.

This phase II trial protocol compares chemo-free ibrutinib/venetoclax/rituximab versus ibrutinib-chemoimmunotherapy in treatment-naive elderly MCL, aiming to establish a new frontline standard.

This case report demonstrates that secondary prostatic MCL can mimic prostate cancer, and transurethral resection can effectively manage resultant urinary retention, highlighting a rare extramedullary presentation.

In untreated mantle cell lymphoma, adding acalabrutinib to bendamustine-rituximab significantly improves progression-free survival with manageable toxicity, offering a potentially safer chemoimmunotherapy combination than ibrutinib-based regimens.

A four-decade analysis demonstrates significant, gradual overall survival improvement in MCL, validating the cumulative clinical impact of evolving therapies from chemotherapy to novel agents and transplant.

A case report highlights chylothorax as a rare clinical presentation of mantle cell lymphoma, underscoring the need to consider malignancy in the differential diagnosis of this condition.

This case report of sequential follicular lymphoma, MCL, and CML highlights the long-term risk of subsequent malignancies and severe infections (COVID-19-induced HLH) following repeated immunochemotherapy.

This case report describes a rare, rapid progression from acute myopericarditis to pericardial calcification after initial CHOP chemotherapy, highlighting a severe, early-onset cardiotoxicity risk with this regimen.

This preclinical study demonstrates potent anti-MCL activity with a triple combination of bendamustine, acalabrutinib, and venetoclax, providing a strong rationale for future clinical trials.

This large real-world analysis of elderly MCL patients shows improved first-line survival with modern therapies, but only modest survival gains after relapse, highlighting a critical unmet clinical need.

This case report describes therapy-related acute megakaryoblastic leukemia after autologous transplant for MCL, highlighting a rare but severe long-term toxicity of intensive consolidation therapy.

This case report details a rare presentation of MCL transformed to DLBCL with urinary symptoms from prostate involvement, highlighting lymphoma as a differential diagnosis requiring aggressive chemoimmunotherapy and transplant.

This review advocates for adding a BTKi to frontline immunochemotherapy for transplant-eligible patients as a new standard of care, while also summarizing its emerging role in older patients.

This preclinical study of a selective immunoproteasome inhibitor in ALL suggests a potential future strategy for MCL to achieve efficacy similar to bortezomib with potentially less off-target toxicity.

This retrospective series of six patients establishes that esophageal multiple lymphomatous polyposis in MCL signifies high tumor burden and a very poor prognosis, with median survival under two years.

This study compares bendamustine-rituximab (BR) versus R-CHOP as initial therapy for transplant-ineligible MCL patients, providing evidence to guide frontline treatment selection in this common clinical setting.

In frontline MCL, pre-treatment ctDNA levels and TP53 mutations predict poor survival, while post-treatment ctDNA clearance identifies patients with favorable outcomes, establishing its clinical utility for prognosis.

This case report describes a rare paraneoplastic syndrome in MCL causing severe thrombocytopenia via both bone marrow failure and immune destruction, which responded to lymphoma-directed chemoimmunotherapy but not standard ITP treatment.

A rare case of co-existing CNS DLBCL and systemic MCL was successfully treated with a multi-modal approach including chemotherapy, ibrutinib bridging, and autologous transplant, achieving 3-year remission.

In a retrospective, mixed-histology study including four MCL patients, splenectomy plus chemotherapy improved survival for aggressive lymphomas presenting with primary splenic involvement, suggesting a potential therapeutic role.

In a prospective cohort of primary GI lymphomas including MCL, routine endoscopic surveillance significantly improved overall survival by detecting relapse early, supporting its role in post-treatment management.

This preclinical study reveals bortezomib, unlike carfilzomib, induces unique multi-organelle stress in endothelial cells, providing a specific mechanism for its cardiovascular toxicity relevant to MCL patients.

The protein TRIM24 regulates autophagy-mediated resistance to the proteasome inhibitor bortezomib, offering a potential new therapeutic target to overcome drug resistance in relapsed/refractory MCL.

Alternating R-DA-EDOCH/R-DHAP induction for young, newly diagnosed MCL patients achieved an 89% complete remission rate and high MRD negativity, offering a potent new frontline intensive chemotherapy option.